Draupnir Bio is a biotechnology company harnessing the natural machinery of the lysosome to develop oral, small molecule degraders of extracellular pathogenic proteins. The rapidly emerging field of targeted protein degradation (TPD) exploits a cell’s own destruction machinery to drive degradation of disease-causing proteins that would otherwise be challenging to target by conventional therapies.

Muna Therapeutics discovers and develops therapies that slow or stop devastating neurodegenerative diseases including Alzheimer’s and Parkinson’s. These disorders impact memory, movement, language, behavior and personality, resulting in disability and death of millions of patients around the globe.

NMD Pharma is a clinical stage company developing novel approaches to restore skeletal muscle function in patients living with neuromuscular diseases characterized by failing communication between motor nerves and skeletal muscle fibres. 

OncoSpear is crafting a research platform to discover receptors for drug candidates and conducting associated operations, encompassing development, marketing, licensing, and sales.